Multifunctional Anti-Lung Cancer LT-Peptides

Ting-Chien Wu [1], Chen-Yi Liao[1], Yu-Ying Lin[2], Jing-Yuan Tseng[1], Shu-Ming Chuang[2], Szu-Yu Liu[2], Chi-Hsiang Wang[2], Shang-Er Su[1], Siang-Wei Wu[1], Ling-I Wang[1], Wei-Ting Chen[1], Sheng-Wen Cheng[1], Cheng-Yen Chuang[2,3], Feng-Di Lung[4,*], and Jinghua Tsai Chang[1,2,5]

[1] Institute of Medicine, Chung Shan Medical University, 110, Sec.1, Chien-Kuo N. Road, Taichung City 402306, Taiwan, ROC.; [2] Institute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec.1, Chien-Kuo N. Road, Taichung City 402306, Taiwan, ROC.; [3] Division of Thoracic Surgery, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung City 407219, Taiwan, ROC.; [4] Department of Chemistry, Tunghai University, Taichung, No. 1727, Sec. 4, Taiwan Boulevard, Taichung City 407224, Taiwan, ROC.; [5] CSMU Lung Cancer Research Center, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan, ROC.

中山醫學大學/醫學研究所
蔡菁華
jinghuat@csmu.edu.tw
0988350017

- LT-peptides are derived from the tumor suppressor Slit2.
- LT-peptides inhibit lung cancer cell proliferation by inhibiting CDK4 activity.
- p53 plays a positive role, whereas JNK1 plays a negative role in LT-peptides-mediated inhibition of lung cancer cell proliferation.
- LT-peptides has no growth inhibitory effect on normal cells, while currently used CKD4 inhibitors can inhibit normal cells and suppress bone marrow, therefore they cannot be used in combination with chemotherapy drugs.
- LT-peptides inhibit tumor growth, and LT1-3 can alleviate the side effects caused by cisplatin.
- LT-cyclic enhances the efficacy of the chemotherapeutic drugs Cisplatin, Docetaxel, Pemetrexed, Gemcitabine, and TKI Osimertinib.
- LT-derived peptides have obtained patents in Taiwan, the United States, China, and Japan. EU patent pending.

- LT1-3 inhibits xenograft tumor growth.





- Combination treatment with LT1-3 and cisplatin promotes animal survival.
- LT1-3 reduces cisplatin-induced side effects.



	Con	CDDP	LT	Support	Combine
Median survival (day)	27.5	37.5	37.5	44.0	47.5



- LT-cyclic inhibits xenograft tumor growth.





- Combined treatment of LT-cyclic and chemotherapy drugs or TKI can synergistically inhibit CL1-5 cell proliferation